首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1957054

日本靜脈輸液市場規模、佔有率、趨勢和預測：按類型、營養成分和地區分類，2026-2034年

Japan Intravenous Solution Market Size, Share, Trends and Forecast by Type, Nutrients, and Region, 2026-2034

出版日期: 2026年02月01日 | 出版商:

IMARC | 英文 141 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年日本靜脈輸液市值為9.6476億美元，預計2034年將達到14.1428億美元。預計2026年至2034年，該市場將以4.34%的複合年成長率成長。

受人口快速老化和需要營養干預的慢性病患者增多的推動，日本靜脈輸液市場正經歷顯著擴張。先進的醫療基礎設施、政府扶持政策以及腸外製劑技術的創新，持續推動市場在各個臨床應用領域的成長。

要點和見解：

按類型分類：預計到 2025 年，部分腸外營養將以 64% 的市佔率主導市場。這是因為部分腸外營養廣泛應用於需要同時進行口服或經腸營養以維持充足營養攝取的患者。
營養成分組成：到2025年，碳水化合物將以32%的市佔率佔據主導地位。這是因為碳水化合物在腸外營養製劑中作為主要能源來源發揮至關重要的作用，並廣泛應用於需要腸外營養支持的各類患者。
區域細分：到2025年，關東地區將佔據35%的市場佔有率，成為最大的細分市場。這主要是由於該地區集中了許多大型醫院、醫療機構和製藥公司，推動了對先進靜脈輸液的需求。
主要企業：日本靜脈輸液市場競爭激烈，本土老牌製藥業者競相從全球醫療保健公司手中奪取市場佔有率。市場參與企業正致力於配方創新、品質提升和策略聯盟，以鞏固其市場地位。

日本靜脈輸液市場受人口結構變化的驅動，該國老年人口比例位居世界前列，需要特殊營養護理的老年人比例極高。 2025年5月，大塚製藥株式會社與ICU Medical公司完成合資企業成立，旨在加強靜脈輸液製劑的生產和創新，打造全球最大的靜脈輸液治療生產網路之一。醫療保健系統日益重視綜合病患管理，推動了對先進腸外營養解決方案的需求，以應對複雜的病理狀況。製劑研發技術的進步拓展了治療應用範圍，引入了多腔輸液袋和客製化營養組合，從而提高了治療效果和患者預後。此外，日本強大的製藥產業在胺基酸製劑、脂肪乳劑、維生素和礦物質製劑等領域不斷創新，建構了滿足多樣化臨床需求的產品系列。家庭腸外營養計畫的日益普及，將市場範圍擴展到醫院之外，而支持性的報銷政策也使患者更容易獲得必要的靜脈輸液治療。

日本靜脈輸液市場趨勢：

先進的多腔袋配方

日本製藥公司正在研發先進的多腔輸液袋系統，將多種營養成分整合於同一輸液袋中，並在給藥前保持其穩定性和無菌性。 2024年9月，大塚製藥株式會社的「Kidparen核准」獲得上市許可。本產品是一種三腔全靜脈營養，將胺基酸、葡萄糖、電解質和維生素整合於同一輸液袋中，適用於慢性腎臟病病患者。這標誌著日本國內在先進腸外營養系統領域取得了顯著進展。這些創新產品將胺基酸、葡萄糖、電解質、脂質和維生素整合於便利的即用輸液袋中，縮短了配製時間並降低了污染風險。這種綜合性單袋解決方案的研發進展有助於簡化臨床工作流程，並提高醫療機構的用藥安全性。

擴大家庭腸外營養服務

在日本靜脈輸液（IVF）市場，居家IVF計畫正日益普及，使慢性疾病患者能夠在醫院外接受營養治療。 2025年，Air Water公司開設了東日本醫療中心，並擴大了包括家庭營養幫浦（HPN幫浦）在內的居家IVF設備的生產。這將滿足日益成長的需求，並有助於提高居家照護患者的生活品質。醫療機構正在開發病患教育計畫和支援系統，以促進安全的居家輸液。這一趨勢既能滿足患者對更高生活品質的需求，又能減輕醫療機構的負擔，並降低相關成本。

個人化營養處方

隨著對個人化患者照護的日益重視，針對特定代謝需求和疾病狀態的客製化腸外營養方案的研發正在不斷推進。日本2024年發布的《重症監護營養管理指南》強調，應根據患者的臨床狀況和代謝需求調整腸外營養的給藥時間和劑量，這標誌著日本全國範圍內重症監護領域正朝著精準營養治療的方向發展。醫療機構正在實施評估通訊協定，以便根據患者的病情、實驗室檢查結果和治療目標進行精準的營養輸注。這種個人化趨勢有助於提高治療效果，並最大限度地減少標準化治療方案帶來的併發症。

2026-2034年市場展望：

受人口結構因素、醫療基礎設施投資和治療方法創新等因素的支撐，日本靜脈輸液市場在預測期內呈現良好的成長前景。老年醫療保健服務、慢性病管理計畫和專業營養支援的持續擴展將維持市場需求。預計該市場在2025年的營收將達到9.6476億美元，並在2026年至2034年間以4.34%的複合年成長率成長，到2034年達到14.1428億美元。

本報告解答的主要問題

1. 日本靜脈輸液市場規模有多大？

2. 日本靜脈輸液市場的預期成長率是多少？

3. 在日本，哪種類型的靜脈輸液市佔率最大？

4. 市場成長的主要促進因素是什麼？

5. 日本靜脈輸液市場面臨的主要挑戰是什麼？

Japan's intravenous solution market is experiencing significant expansion driven by the nation's rapidly aging population and rising prevalence of chronic diseases requiring nutritional intervention. The advanced healthcare infrastructure, coupled with supportive government policies and technological innovations in parenteral formulations, continues to fuel market growth across diverse clinical applications.

KEY TAKEAWAYS AND INSIGHTS:

By Type: Partial parenteral nutrition dominates the market with a share of 64% in 2025 , driven by its widespread application in patients requiring supplemental nutritional support alongside oral or enteral feeding to maintain adequate nutrient intake.
By Nutrients: Carbohydrates lead the market with a share of 32% in 2025 , owing to their essential role as primary energy sources in parenteral nutrition formulations and widespread utilization across diverse patient populations requiring intravenous nutritional support.
By Region: Kanto Region represents the largest segment with a market share of 35% in 2025 , attributed to its concentration of leading hospitals, healthcare facilities, and pharmaceutical companies driving demand for advanced intravenous solutions (IV).
Key Players: The Japan intravenous solution market exhibits a competitive landscape with established domestic pharmaceutical manufacturers competing alongside global healthcare corporations. Market participants focus on formulation innovations, quality enhancements, and strategic collaborations to strengthen their market positioning.

Japan's intravenous solution market is propelled by the nation's demographic transformation, characterized by one of the world's highest proportions of elderly citizens requiring specialized nutritional care. In May 2025, Otsuka Pharmaceutical Factory and ICU Medical completed the establishment of a joint venture aimed at bolstering IV solutions manufacturing and innovation, creating one of the largest global infusion therapy production networks. The healthcare system's emphasis on comprehensive patient management drives demand for advanced parenteral nutrition solutions addressing complex medical conditions. Technological advancements in formulation development have expanded treatment applications, introducing multi-chamber bags and customized nutrient combinations that enhance therapeutic efficacy and patient outcomes. Furthermore, Japan's robust pharmaceutical industry continues to innovate in areas including amino acid solutions, lipid emulsions, and vitamin-mineral preparations, creating diverse product portfolios catering to varied clinical requirements. The growing adoption of home parenteral nutrition programs is extending market reach beyond hospital settings, while supportive reimbursement policies facilitate patient access to essential intravenous therapies.

JAPAN INTRAVENOUS SOLUTION MARKET TRENDS:

Advanced Multi-Chamber Bag Formulations

Japanese pharmaceutical manufacturers are developing sophisticated multi-chamber bag systems that combine multiple nutritional components while maintaining stability and sterility until administration. In September 2024, Otsuka Pharmaceutical Factory obtained marketing approval for "KIDPAREN Injection," a three-chamber total parenteral nutrition solution that integrates amino acids, glucose, electrolytes, and vitamins in a single bag for patients with chronic kidney disease, illustrating local industry progress in advanced IV nutritional systems. These innovations integrate amino acids, glucose, electrolytes, lipids, and vitamins in convenient ready-to-use formats, reducing preparation time and contamination risks. The advancement toward comprehensive single-bag solutions streamlines clinical workflows and improves medication safety in healthcare settings.

Expansion of Home Parenteral Nutrition Services

The Japan intravenous solution market is witnessing growing adoption of home-based parenteral nutrition programs enabling patients with chronic conditions to receive nutritional therapy outside hospital environments. In 2025, Air-Water expanded home infusion equipment production, including HPN pumps, by opening the East Japan Medical Center, addressing growing demand and enhancing quality of life for home care patients. Healthcare providers are developing patient education initiatives and support systems facilitating safe home administration. This trend addresses patient preferences for improved quality of life while reducing healthcare facility burdens and associated costs.

Personalized Nutritional Formulations

Increasing emphasis on individualized patient care is driving development of customized parenteral nutrition solutions tailored to specific metabolic requirements and disease states. Japan's 2024 Critical Care Nutrition Guideline emphasizes tailoring parenteral nutrition timing and dosing to patients' clinical conditions and metabolic needs, signaling a nationwide shift toward precise nutrient therapy in critical care. Healthcare institutions are implementing assessment protocols enabling precise nutrient dosing based on patient conditions, laboratory values, and therapeutic goals. This personalization trend enhances treatment effectiveness and minimizes complications associated with standardized approaches.

MARKET OUTLOOK 2026-2034:

The Japan intravenous solution market demonstrates favorable growth prospects throughout the forecast period, supported by demographic factors, healthcare infrastructure investments, and therapeutic innovations. Continued expansion of geriatric care services, chronic disease management programs, and specialized nutritional support will sustain market demand. The market generated a revenue of USD 964.76 Million in 2025 and is projected to reach a revenue of USD 1,414.28 Million by 2034, growing at a compound annual growth rate of 4.34% from 2026-2034.

JAPAN INTRAVENOUS SOLUTION MARKET REPORT SEGMENTATION:

Type Insights :

Partial Parenteral Nutrition
Total Parenteral Nutrition

The partial parenteral nutrition dominates with a market share of 64% of the total Japan intravenous solution market in 2025.

Partial parenteral nutrition represents the largest type of segment in Japan's intravenous solution market, providing supplemental nutritional support to patients who can receive some nutrition through oral or enteral routes but require additional intravenous nutrients to meet their metabolic requirements. According to a 2024 report, Japanese hospitals have increasingly strengthened multidisciplinary Nutrition Support Teams (NSTs) to enhance parenteral nutrition practice, with clinical data showing NST-led interventions significantly improved implementation of recommended nutrition therapies, reflecting stronger institutional focus on appropriate nutrition support. This approach is widely utilized across hospital settings for patients recovering from surgery, experiencing temporary gastrointestinal dysfunction, or requiring enhanced nutritional intake during illness recovery periods.

The segment's dominance reflects clinical preferences for maintaining gastrointestinal function whenever possible while ensuring adequate nutrient delivery. Japanese healthcare protocols emphasize early enteral feeding combined with parenteral supplementation, driving demand for partial parenteral nutrition solutions. Manufacturers continue developing specialized formulations addressing specific clinical scenarios including post-operative care, oncology support, and geriatric nutrition, expanding the segment's application scope across diverse patient populations.

Nutrients Insights :

Carbohydrates
Salts and Electrolytes
Minerals
Vitamins
Amino Acids

The carbohydrates leads with a share of 32% of the total Japan intravenous solution market in 2025.

Carbohydrates constitute the leading nutrient segment in Japan's intravenous solution market, serving as the primary energy source in parenteral nutrition formulations. Glucose-based solutions provide essential caloric support for patients unable to maintain adequate oral intake, supporting metabolic functions and tissue preservation during periods of nutritional compromise. The widespread requirement for energy provision across virtually all parenteral nutrition applications ensures consistent demand for carbohydrate solutions.

Japanese pharmaceutical manufacturers offer diverse carbohydrate formulations with varying concentrations and compositions tailored to specific clinical requirements. The segment benefits from established clinical protocols integrating glucose administration into standard parenteral nutrition regimens across medical specialties. Ongoing research focuses on optimizing carbohydrate delivery rates and combinations with other nutrients to enhance metabolic outcomes and minimize complications associated with intravenous glucose administration.

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region

The Kanto Region exhibits a clear dominance with a 35% share of the total Japan intravenous solution market in 2025.

The Kanto Region dominates Japan's intravenous solution market with the largest share, anchored by Tokyo's concentration of leading university hospitals, specialized medical centers, and pharmaceutical headquarters. The region's advanced healthcare infrastructure and high population density generate substantial demand for parenteral nutrition solutions across acute care and chronic disease management applications.

Additionally, Kanto's robust research ecosystem drives innovation in intravenous therapies, with numerous clinical trials and pilot programs evaluating novel formulations and multi-chamber bag systems. Collaboration between hospitals, biotech startups, and established pharmaceutical companies accelerates product development, ensuring rapid adoption of advanced IV solutions to meet the evolving nutritional needs of diverse patient populations.

MARKET DYNAMICS:

GROWTH DRIVERS:

Why is the Japan Intravenous Solution Market Growing ?

Rapidly Aging Population Requiring Nutritional Support

Japan possesses one of the world's most aged populations, with elderly citizens representing an expanding proportion of the total population. As of September 2025, an estimated 36.19 million Japanese citizens, nearly 29.4 % of the population, were aged 65 or older, the highest proportion recorded and highlighting Japan's status as the most aged society globally. This demographic transformation significantly influences healthcare demand, as older individuals frequently experience conditions affecting nutritional intake including swallowing difficulties, gastrointestinal disorders, and chronic diseases requiring medical intervention. The growing geriatric population creates sustained demand for parenteral nutrition solutions supporting patients unable to meet nutritional requirements through conventional feeding methods. Healthcare providers increasingly recognize the importance of adequate nutrition in elderly patient outcomes, driving adoption of intravenous solutions across hospitals, long-term care facilities, and home care settings.

Rising Prevalence of Chronic Diseases and Malnutrition

The increasing burden of chronic diseases including cancer, gastrointestinal disorders, and metabolic conditions drives demand for specialized nutritional interventions in Japan. According to reports, Japan reported 316,900 ulcerative colitis and 95,700 Crohn's cases, a 40 % rise over eight years, driving increased demand for comprehensive nutritional support, including parenteral nutrition. Patients with conditions affecting nutrient absorption or requiring intensive medical treatments often develop malnutrition necessitating parenteral support. Cancer patients undergoing chemotherapy or radiation therapy frequently require intravenous nutrition to maintain strength and support immune function during treatment periods. Similarly, patients with inflammatory bowel disease, short bowel syndrome, and other gastrointestinal conditions depend on parenteral nutrition for survival and quality of life maintenance, creating consistent market demand across clinical specialties.

Technological Advancements in Parenteral Formulations

Continuous innovation in parenteral nutrition technology expands market opportunities through improved product safety, efficacy, and convenience. Japanese pharmaceutical manufacturers develop advanced multi-chamber bag systems combining multiple nutritional components with extended stability profiles, enhancing clinical utility and reducing preparation requirements. Novel lipid emulsions incorporating beneficial fatty acid profiles improve patient tolerance and metabolic outcomes. Additionally, specialized formulations addressing specific disease states and patient populations broaden therapeutic applications. These technological advancements increase healthcare provider confidence in parenteral nutrition therapies, driving adoption across diverse clinical settings and patient populations.

MARKET RESTRAINTS:

What Challenges the Japan Intravenous Solution Market is Facing?

Complications Associated with Parenteral Nutrition Administration

Intravenous nutrition administration carries inherent risks including catheter-related infections, metabolic complications, and liver dysfunction that require careful patient monitoring and management. These potential complications necessitate specialized healthcare professional expertise and sophisticated monitoring protocols, limiting administration settings and increasing overall treatment costs. Concerns regarding long-term parenteral nutrition complications influence clinical decision-making toward alternative feeding methods when feasible.

High Treatment Costs and Reimbursement Pressures

Parenteral nutrition therapies involve substantial costs encompassing specialized formulations, administration equipment, professional monitoring, and potential complication management. Healthcare budget constraints and reimbursement system pressures create challenges for widespread therapy adoption, particularly for long-term treatments. Cost considerations influence clinical decisions regarding parenteral versus enteral nutrition approaches and treatment duration, potentially limiting market expansion in certain patient segments.

Shortage of Specialized Healthcare Professionals

Effective parenteral nutrition management requires healthcare professionals with specialized training in nutritional assessment, formulation prescription, and complication monitoring. Japan's healthcare workforce faces demographic challenges reflecting broader population trends, creating potential shortages of qualified personnel for specialized nutrition support services. Limited availability of trained nutrition support teams may constrain service expansion, particularly in regions with fewer major medical centers.

COMPETITIVE LANDSCAPE:

The Japan intravenous solution market exhibits a moderately consolidated competitive structure characterized by established domestic pharmaceutical manufacturers alongside global healthcare corporations. Market participants compete through product innovation, quality assurance, manufacturing capabilities, and distribution network strength. Domestic companies leverage understanding of local regulatory requirements and healthcare system dynamics, while international players contribute global research expertise and comprehensive product portfolios. Strategic activities including product launches, formulation improvements, and manufacturing investments characterize competitive dynamics. Manufacturers increasingly emphasize comprehensive nutritional solution portfolios addressing diverse patient needs, specialty formulations for specific clinical applications, and customer support services differentiating their market positioning.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the Japan intravenous solution market?

2. What is the projected growth rate of the Japan intravenous solution market?

3. Which type held the largest Japan intravenous solution market share?

4. What are the key factors driving market growth?

5. What are the major challenges facing the Japan intravenous solution market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Intravenous Solution Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Intravenous Solution Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Intravenous Solution Market - Breakup by Type

6.1 Partial Parenteral Nutrition
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Total Parenteral Nutrition
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)

7 Japan Intravenous Solution Market - Breakup by Nutrients

7.1 Carbohydrates
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Salts and Electrolytes
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Minerals
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Vitamins
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Amino Acids
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)

8 Japan Intravenous Solution Market - Breakup by Region

8.1 Kanto Region
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Breakup by Type
- 8.1.4 Market Breakup by Nutrients
- 8.1.5 Key Players
- 8.1.6 Market Forecast (2026-2034)
8.2 Kansai/Kinki Region
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Breakup by Type
- 8.2.4 Market Breakup by Nutrients
- 8.2.5 Key Players
- 8.2.6 Market Forecast (2026-2034)
8.3 Central/ Chubu Region
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2020-2025)
- 8.3.3 Market Breakup by Type
- 8.3.4 Market Breakup by Nutrients
- 8.3.5 Key Players
- 8.3.6 Market Forecast (2026-2034)
8.4 Kyushu-Okinawa Region
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2020-2025)
- 8.4.3 Market Breakup by Type
- 8.4.4 Market Breakup by Nutrients
- 8.4.5 Key Players
- 8.4.6 Market Forecast (2026-2034)
8.5 Tohoku Region
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2020-2025)
- 8.5.3 Market Breakup by Type
- 8.5.4 Market Breakup by Nutrients
- 8.5.5 Key Players
- 8.5.6 Market Forecast (2026-2034)
8.6 Chugoku Region
- 8.6.1 Overview
- 8.6.2 Historical and Current Market Trends (2020-2025)
- 8.6.3 Market Breakup by Type
- 8.6.4 Market Breakup by Nutrients
- 8.6.5 Key Players
- 8.6.6 Market Forecast (2026-2034)
8.7 Hokkaido Region
- 8.7.1 Overview
- 8.7.2 Historical and Current Market Trends (2020-2025)
- 8.7.3 Market Breakup by Type
- 8.7.4 Market Breakup by Nutrients
- 8.7.5 Key Players
- 8.7.6 Market Forecast (2026-2034)
8.8 Shikoku Region
- 8.8.1 Overview
- 8.8.2 Historical and Current Market Trends (2020-2025)
- 8.8.3 Market Breakup by Type
- 8.8.4 Market Breakup by Nutrients
- 8.8.5 Key Players
- 8.8.6 Market Forecast (2026-2034)

9 Japan Intravenous Solution Market - Competitive Landscape

9.1 Overview
9.2 Market Structure
9.3 Market Player Positioning
9.4 Top Winning Strategies
9.5 Competitive Dashboard
9.6 Company Evaluation Quadrant

10 Profiles of Key Players

10.1 Company A
- 10.1.1 Business Overview
- 10.1.2 Products Offered
- 10.1.3 Business Strategies
- 10.1.4 SWOT Analysis
- 10.1.5 Major News and Events
10.2 Company B
- 10.2.1 Business Overview
- 10.2.2 Products Offered
- 10.2.3 Business Strategies
- 10.2.4 SWOT Analysis
- 10.2.5 Major News and Events
10.3 Company C
- 10.3.1 Business Overview
- 10.3.2 Products Offered
- 10.3.3 Business Strategies
- 10.3.4 SWOT Analysis
- 10.3.5 Major News and Events
10.4 Company D
- 10.4.1 Business Overview
- 10.4.2 Products Offered
- 10.4.3 Business Strategies
- 10.4.4 SWOT Analysis
- 10.4.5 Major News and Events
10.5 Company E
- 10.5.1 Business Overview
- 10.5.2 Products Offered
- 10.5.3 Business Strategies
- 10.5.4 SWOT Analysis
- 10.5.5 Major News and Events

11 Japan Intravenous Solution Market - Industry Analysis

11.1 Drivers, Restraints, and Opportunities
- 11.1.1 Overview
- 11.1.2 Drivers
- 11.1.3 Restraints
- 11.1.4 Opportunities
11.2 Porters Five Forces Analysis
- 11.2.1 Overview
- 11.2.2 Bargaining Power of Buyers
- 11.2.3 Bargaining Power of Suppliers
- 11.2.4 Degree of Competition
- 11.2.5 Threat of New Entrants
- 11.2.6 Threat of Substitutes
11.3 Value Chain Analysis